Clinical trial · Observational
The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian Cancer
NCT06798610CI-TRIAL-00085242completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Advanced-stage ovarian cancer surgery is a procedure that inherently carries a high risk of mortality and morbidity. However, there are some uncertainties regarding whether these complications can be predicted before the operation. In this study, we aimed to examine the relationship between complications and inflammation.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Complications | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients who underwent cytoreductive surgery due to advanced-stage ovarian cancer
- description
- The study will investigate the complications that develop within one month following cytoreductive surgery in patients with advanced-stage ovarian cancer. It will explore the relationship between these complications and preoperative inflammatory markers
Primary outcomes (1)
- measure
- Correlation Between Preoperative Inflammatory Markers and Postoperative Complications
- timeFrame
- Preoperative inflammatory markers will be measured within 1 week before surgery. Postoperative complications will be assessed within 30 days after surgery.
- description
- This measure will examine the relationship between preoperative inflammatory markers and postoperative complications. The levels of inflammatory markers may be used to predict the risk of complications and can guide treatment approaches aimed at improving the recovery process following surgery.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * The inclusion criteria of the patients were determined as those who underwent surgery with the diagnosis of FIGO Stage IIIc and IV epithelial ovarian cancer. Exclusion Criteria: * The exclusion criteria of the study were patients who had recently undergone blood transfusion or bacterial or viral infection within two weeks before surgery. * Pregnant patients or patients with hematological diseases. * Patients with thrombotic diseases. * Patients with immunological diseases. * Patients with severe liver or kidney diseases, patients with a previous history of cancer. * Patients receiving anticoagulant and/or antiplatelet therapy due to venous or arterial thromboembolism.
References
Publications (0)
Data not yet available
No reference posted for this study.